Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4924MR)

This product GTTS-WQ4924MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNFRSF17 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001192.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 608
UniProt ID Q02223
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ4924MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8527MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Hu3F8
GTTS-WQ7713MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GEXMab73
GTTS-WQ13350MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-06801591
GTTS-WQ817MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-085
GTTS-WQ6417MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CT-011
GTTS-WQ5076MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CAM-3001
GTTS-WQ14978MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SHR-1314
GTTS-WQ12104MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MOR-03087
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW